The MRC Confidence in Concepts at UCL Fund 2014
Lead Research Organisation:
University College London
Department Name: UNLISTED
Abstract
Abstracts are not currently available in GtR for all funded research. This is normally because the abstract was not required at the time of proposal submission, but may be because it included sensitive information such as personal details.
Technical Summary
The Confidence in Concept scheme is a key part of MRC’s translational research strategy and provides annual awards to institutions, to be used flexibly to support the earliest stages of multiple translational research projects. The award can be used by the institution to support a number of preliminary-stage translational projects. The projects supported should aim to provide sufficient preliminary data to establish the viability of an approach –– before seeking more substantive funding. It is intended to accelerate the transition from discovery research to translational development projects by supporting preliminary work or feasibility studies to establish the viability of an approach.
Organisations
People |
ORCID iD |
Publications
Vink CA
(2017)
Eliminating HIV-1 Packaging Sequences from Lentiviral Vector Proviruses Enhances Safety and Expedites Gene Transfer for Gene Therapy.
in Molecular therapy : the journal of the American Society of Gene Therapy
Schuh CMAP
(2018)
An Optimized Collagen-Fibrin Blend Engineered Neural Tissue Promotes Peripheral Nerve Repair.
in Tissue engineering. Part A
Santos C
(2020)
Impaired folate 1-carbon metabolism causes formate-preventable hydrocephalus in glycine decarboxylase-deficient mice.
in The Journal of clinical investigation
O'Rourke C
(2018)
An allogeneic 'off the shelf' therapeutic strategy for peripheral nerve tissue engineering using clinical grade human neural stem cells.
in Scientific reports
Meran L
(2020)
Engineering transplantable jejunal mucosal grafts using patient-derived organoids from children with intestinal failure.
in Nature medicine
McGregor C
(2016)
Physical equivalency of wild type and galactose a 1,3 galactose free porcine pericardium; a new source material for bioprosthetic heart valves.
in Acta biomaterialia
Leung KY
(2020)
Regulation of glycine metabolism by the glycine cleavage system and conjugation pathway in mouse models of non-ketotic hyperglycinemia.
in Journal of inherited metabolic disease
Kao VY
(2016)
Haemophilia B curative FIX production from a low dose UCOE-based lentiviral vector following hepatic pre-natal delivery.
in Current gene therapy
Hawkins KE
(2016)
NRF2 Orchestrates the Metabolic Shift during Induced Pluripotent Stem Cell Reprogramming.
in Cell reports
| Description | A Chemical Imaging Platform for Discovery Biosciences (CIP-DB). |
| Amount | £353,040 (GBP) |
| Funding ID | BB/R013667/1 |
| Organisation | Biotechnology and Biological Sciences Research Council (BBSRC) |
| Sector | Public |
| Country | United Kingdom |
| Start | 05/2018 |
| End | 04/2019 |
| Description | AMR, Dagan Jenkins |
| Amount | £160,610 (GBP) |
| Organisation | Action Medical Research |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | 09/2016 |
| End | 12/2017 |
| Description | Action Medical Research Project Grant, Greene |
| Amount | £177,915 (GBP) |
| Funding ID | GN2403 |
| Organisation | Action Medical Research |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | 09/2016 |
| End | 12/2017 |
| Description | Daphne Jackson Memorial Trust Fellowship, Greene |
| Amount | £49,908 (GBP) |
| Organisation | University of Surrey |
| Department | Daphne Jackson Trust |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | 05/2017 |
| End | 12/2018 |
| Description | GOSH BRC, Dagan Jenkins |
| Amount | £49,878 (GBP) |
| Organisation | Great Ormond Street Hospital (GOSH) |
| Sector | Hospitals |
| Country | United Kingdom |
| Start | 09/2016 |
| End | 08/2017 |
| Description | Gene therapy for Non-Ketotic Hyperglycinemia |
| Amount | £373,597 (GBP) |
| Organisation | LifeArc |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | 09/2019 |
| End | 09/2022 |
| Description | Investment Accelerator Pilot - Phillips |
| Amount | £150,000 (GBP) |
| Organisation | Innovate UK |
| Sector | Public |
| Country | United Kingdom |
| Start | |
| Description | Joseph's Goal NKH Charity, Greene |
| Amount | £160,000 (GBP) |
| Organisation | NKH Charity |
| Sector | Charity/Non Profit |
| Country | United States |
| Start | 09/2016 |
| End | 12/2017 |
| Description | MRC DPFS, McGregor |
| Amount | £1,094,729 (GBP) |
| Organisation | Medical Research Council (MRC) |
| Sector | Public |
| Country | United Kingdom |
| Start | 03/2018 |
| End | 02/2021 |
| Description | Mathematical Modelling Led Design of Tissue-Engineered Constructs: A New Paradigm for Peripheral Nerve Repair (NerveDesign) |
| Amount | £1,080,646 (GBP) |
| Funding ID | EP/R004463/1 |
| Organisation | Engineering and Physical Sciences Research Council (EPSRC) |
| Sector | Public |
| Country | United Kingdom |
| Start | 01/2018 |
| End | 12/2022 |
| Description | PoC fund - Waddington |
| Amount | £13,995 (GBP) |
| Organisation | UCL Business |
| Sector | Private |
| Country | United Kingdom |
| Start | |
| Description | Therapeutic targeting of LRG1 in tumour angiogenesis - John Greenwood |
| Amount | £1,100,000 (GBP) |
| Organisation | University College London |
| Department | Technology Fund |
| Sector | Academic/University |
| Country | United Kingdom |
| Start | 09/2019 |
| End | 09/2020 |
| Description | Tissue-derived ECM hydrogels for peripheral nerve repair |
| Amount | £75,000 (GBP) |
| Funding ID | 1786197 |
| Organisation | Engineering and Physical Sciences Research Council (EPSRC) |
| Sector | Public |
| Country | United Kingdom |
| Start | 09/2016 |
| End | 09/2020 |
| Description | UCL TAS fund, Waddington |
| Amount | £72,866 (GBP) |
| Organisation | Medical Research Council (MRC) |
| Sector | Public |
| Country | United Kingdom |
| Start | 01/2018 |
| End | 12/2018 |
| Description | UCL Technology Fund, Philips |
| Amount | £100,000 (GBP) |
| Organisation | University College London |
| Sector | Academic/University |
| Country | United Kingdom |
| Start | 01/2017 |
| End | 12/2017 |
| Description | UCLB Tech Fund, Greenwood |
| Amount | £100,000 (GBP) |
| Organisation | University College London |
| Sector | Academic/University |
| Country | United Kingdom |
| Start | 09/2017 |
| End | 09/2018 |
| Description | WT Innovator - Nick Greene |
| Amount | £365,837 (GBP) |
| Funding ID | 210774/Z/18/Z |
| Organisation | Wellcome Trust |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | |
| Description | WT Investigator Award, John Greenwood |
| Amount | £1,714,270 (GBP) |
| Funding ID | 206413/Z/17/Z |
| Organisation | Wellcome Trust |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | 06/2017 |
| End | 05/2022 |
| Title | ANTIBODY WHICH BINDS LRG1 AND METHODS OF USE |
| Description | The invention provides an antibody or fragment thereof that specifically binds to human Lrgl. |
| IP Reference | CA2977888 |
| Protection | Patent application published |
| Year Protection Granted | 2016 |
| Licensed | Yes |
| Impact | still in development |
| Title | BIOPROSTHETIC HEART VALVE |
| Description | A bioprosthetic heart valve and the method for fabricating said bioprosthetic heart valve; the method comprising: providing: a sheet of biological tissue (11); a sheet of a biocompatible material (2), and a stent (4), the stent (4) having an upstream edge (41) and a downstream edge (42) as well as an inner surface and an outer surface; attaching the biological tissue (11) to the biocompatible material (2) along a suture line (3); folding the biocompatible material to form a tubular structure with the attached biological tissue located on the inner surface of the tubular structure, the biological tissue forming the leaflets (11) of the heart valve; securing the stent around the outer surface of the tubular structure such that the tubular structure extends in an upstream direction beyond the upstream edge of the stent and in a downstream direction beyond the downstream edge of the stent; cutting at least one region of the biocompatible material at the downstream end of the tubular structure; folding the biocompatible material at the cut region away from the biological tissue and around the downstream edge of the stent and securing it to the outer surface of the stent; and folding the biocompatible material at the upstream end of the tubular structure around the upstream edge of the stent and attaching to the outer surface of the stent so that the inner and outer surfaces of the stent are covered with no more than a single layer of the biocompatible material. |
| IP Reference | WO2018011592 |
| Protection | Patent application published |
| Year Protection Granted | 2018 |
| Licensed | No |
| Impact | None as yet |
| Title | COMPOSITION COMPRISING VEGF ANTAGONISTS AND A CATIONIC PEPTIDE AND USES THEREOF |
| Description | The invention relates compositions comprising a small cationic peptide and a VEGF antagonist, and the use of such compositions in the treatment or prevention of conditions characterised by VEGF dysfunction, for example vasculoproliferative conditions, particularly in the eye. |
| IP Reference | WO2019038552 |
| Protection | Patent application published |
| Year Protection Granted | 2019 |
| Licensed | No |
| Impact | still in development |
| Title | Intranasal delivery of fluorescent marker |
| Description | The present invention provides a method of diagnosing a CNS disorder comprising administering a fluorescent marker of retinal integrity to a subject and generating an image of the subject's eye, wherein the fluorescent marker is delivered by intranasal administration is also provided and fluorescent markers of retinal integrity for use in such methods. Also provided is a pharmaceutical composition comprising an annex in or a functional fragment or derivative thereof conjugated to a compound of 2 kDa or less, wherein the composition comprises annex in or a functional fragment or derivative thereof conjugated at a concentration of at least mg/ml. |
| IP Reference | AU2019259198 |
| Protection | Patent application published |
| Year Protection Granted | 2020 |
| Licensed | No |
| Impact | Still in development |
| Title | RETROVIRAL VECTORS |
| Description | There is disclosed a retroviral vector comprising a primer binding site, a long terminal repeat and an RNA packaging sequence, wherein the RNA packaging sequence is located 3' of the long terminal repeat and no long terminal repeat is located 3' of the RNA packaging sequence such that reverse transcription initiated at the primer binding site does not lead to reverse transcription of the RNA packaging sequence into vector DNA in a target cell. Also described is a host cell, a virion, a pharmaceutical composition, a method and uses including or involving the vector described above. Further, a cell or transgenic animal produced by using the vector is also described. |
| IP Reference | WO2015056014 |
| Protection | Patent application published |
| Year Protection Granted | 2015 |
| Licensed | No |
| Impact | too early |
| Title | TREATMENT |
| Description | The invention provides an antibody or fragment thereof that specifically binds to human Lrg1. |
| IP Reference | US2018028609 |
| Protection | Patent application published |
| Year Protection Granted | 2018 |
| Licensed | Yes |
| Impact | Still in development |
| Title | TREATMENT |
| Description | The invention provides an antibody or fragment thereof that specifically binds to human Lrg1. |
| IP Reference | US2020330591 |
| Protection | Patent application published |
| Year Protection Granted | 2020 |
| Licensed | Yes |
| Impact | still in development |
| Title | TREATMENT |
| Description | The invention provides an antibody or fragment thereof that specifically binds to human Lrgl. |
| IP Reference | WO2016135462 |
| Protection | Patent application published |
| Year Protection Granted | 2016 |
| Licensed | Yes |
| Impact | still in development |
| Title | TREATMENT OF CANCER |
| Description | This invention relates to the field of molecular physiology. Specifically, this invention relates to the prevention and/or treatment of cancer. Leucine-rich alpha-2-glycoprotein (Lrg1) has been demonstrated to be expressed in a range of cancer cells. Antagonists of Lrg1 can be used to prevent and/or treat cancer by an effect on neoplastic cells. |
| IP Reference | US2015132226 |
| Protection | Patent application published |
| Year Protection Granted | 2015 |
| Licensed | No |
| Impact | none as yet |
| Title | USE OF ANTIBODIES AND ANTAGONISTS DIRECTED AGAINST LRG1 IN TREATMENT |
| Description | Antibody directed to LRG1 |
| IP Reference | EP3262069 |
| Protection | Patent application published |
| Year Protection Granted | 2018 |
| Licensed | Yes |
| Impact | still in development |